Confidential information

The law of confidentiality is often the best way of protecting trade secrets and valuable know-how where these are not otherwise adequately protected by other means (eg via intellectual property rights), or where using other types of protection is unattractive for commercial reasons.

Even if other types of rights exist (eg patent rights in the case of patented inventions), often the real value of an invention or new piece of technology does not lie just in the invention itself, but also in the associated know-how, training and guidance required to fully exploit it. Therefore, the law of confidentiality also helps to protect valuable information associated with (for instance) an invention, along with financial, customer and similar confidential information that a business holds.

Examples of items which might be considered confidential within a business include:

•
commercial records such as price lists, customer lists, details of customers, suppliers, business partners and relationships with regulators or other third parties
•
unpublished copyright works
•
mathematical formulae and manufacturing techniques, processes, designs, drawings and engineering
•
secure codes and algorithms
•
personal employee information such as compensation arrangements, benefits, hours or work etc

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

AI developers, users to see guidelines on EU AI Act interplay after legal deadline

MLex: The European Commission will issue guidelines on how the EU AI Act interacts with other EU laws such as the EU GDPR, product safety legislation, platform regulations and copyright rules only around the third quarter of 2026—meaning just before or just after the law’s high-risk obligations will take effect. The delay adds pressure on the commission as it weighs whether to pause the EU AI Act’s high-risk requirements.

MHRA and NICE open access to streamlined approval pathway for early access medicines ahead of schedule

The Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) are offering designated early access medicines manufacturers access to the aligned streamlined approvals pathway six months earlier than projected. The aligned pathway combines the MHRA’s licensing process and NICE’s value assessment process, meaning decisions will be published at the same time, instead of consecutively. This will reduce the 90-day gap between marketing authorisation and NICE guidance decisions, accelerating patient access and support for the NHS to provide industry with a more efficient route to market. A new fully integrated joint scientific advice service, launching by April 2026, will provide a single-entry point for coordinated advice from the MHRA and NICE to help avoid delays and support alignment. Pharmaceutical companies should register medicinal products on UK PharmaScan at least three years before MA licensing and to engage early with the regulators.

Life Sciences weekly highlights—9 October 2025

This week's edition of Life Sciences weekly highlights includes analysis by Taylor Wessing LLP of damages quantification methodologies in the long-running Merck v Merck Sharpe & Dohme trade mark infringement case. Also included, is several stories covering the European Commission announcing its bold Apply AI and AI in Science strategies to advance the adoption of AI in scientific research, the Commission also has launched the AI Act Service Desk and Single Information Platform to support implementation of the AI Act, the EMA has launched a survey to identify key research priorities for AI in the development and evaluation of medicines and published its European Medicines Agencies Network Data Strategy, MedTech Europe published a reflection paper responding to the Commission’s Chemicals Industry Action Plan calling for realistic transition pathways and continued access to essential chemicals like PFAS in their downstream use for critical medical technologies and the DHSC launched a consultation to shape new regulations on the sale and composition of tobacco, vape and nicotine products. Further news includes stories that the British health technology industry body (ABHI) published its response to an EU consultation on proposed revisions to the EU medical device legislation, the EU pharmaceutical industry called for refinement of certain provisions in the EU’s General Pharmaceutical Legislation reform package, the UK High Court found that the DHSC was still entitled to some damages for Medpro’s breach of contract despite the DHSC failing to reject the PPE gowns within time, the MHRA halved clinical trial approval times to 41 days following regulatory reforms and digital platforms introduced in 2023, and the Commission has formally withdrawn the AI Liability Act; among other stories.

DHSC launches call for evidence on tobacco and vape retail licensing scheme

The Department of Health and Social Care (DHSC) has launched a call for evidence to shape new regulations on the sale and composition of tobacco, vape and nicotine products as part of the government’s Plan for Change and the Tobacco and Vapes Bill, which aims to create a smoke-free generation and protect children from nicotine addiction. The proposals would require all retailers to obtain a licence to sell such products, closing a gap in the law that currently allows unregulated sales and enabling stronger action against rogue traders. Retailers selling without a licence could face unlimited fines or fixed penalties of £2,500 in England and Wales, and up to £5,000 in Northern Ireland. Views are also sought on vape flavours and ingredients, nicotine strength limits, product design, and a national registration system to improve market oversight and consumer safety. The evidence gathered will inform secondary legislation supporting measures such as restrictions on advertising, sponsorship and product displays. The call for evidence closes on 3 December 2025.